Literature DB >> 21492125

Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Yusuke Takeda1, Chiaki Nakaseko, Hiroaki Tanaka, Masahiro Takeuchi, Makiko Yui, Atsunori Saraya, Satoru Miyagi, Changshan Wang, Satomi Tanaka, Chikako Ohwada, Emiko Sakaida, Naoto Yamaguchi, Koutaro Yokote, Lothar Hennighausen, Atsushi Iwama.   

Abstract

Myeloproliferative neoplasms (MPN), a group of haematopoietic stem cell (HSC) disorders, are often accompanied by myelofibrosis. We previously identified the fusion of the ETV6 gene to the LYN gene (ETV6-LYN) in idiopathic myelofibrosis with ins(12;8)(p13;q11q21). The introduction of ETV6-LYN into HSCs resulted in fatal MPN with massive myelofibrosis in mice, implicating the rearranged LYN kinase in the pathogenesis of MPN with myelofibrosis. However, the signalling molecules directly downstream from and activated by ETV6-LYN remain unknown. In this study, we demonstrated that the direct activation of STAT5 by ETV6-LYN is crucial for the development of MPN. ETV6-LYN was constitutively active as a kinase through autophosphorylation. ETV6-LYN, but not its kinase-dead mutant, supported cytokine-free proliferation of haematopoietic cells. STAT5 was activated in a JAK2-independent manner in ETV6-LYN-expressing cells. ETV6-LYN interacted with STAT5 and directly activated STAT5 both in vitro and in vivo. Of note, ETV6-LYN did not support the formation of colonies by Stat5-deficient HSCs under cytokine-free conditions and the capacity of ETV6-LYN to induce MPN with myelofibrosis was profoundly attenuated in a Stat5-null background. These findings define STAT5 as a direct target of ETV6-LYN and unveil the LYN-STAT5 axis as a novel pathway to augment proliferative signals in MPN and leukaemia.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492125      PMCID: PMC3091948          DOI: 10.1111/j.1365-2141.2011.08663.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  38 in total

1.  Clonal expansion of non-leukemic cells expressing two novel MLL-ELL variants differing in transforming activity.

Authors:  M Takeuchi; C Nakaseko; S Miyagi; Y Takeda; S Ozawa; C Ohwada; R Cho; M Nishimura; Y Saito; A Iwama
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 2.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

3.  Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.

Authors:  Michael Heuser; Laura M Sly; Bob Argiropoulos; Florian Kuchenbauer; Courteney Lai; Andrew Weng; Malina Leung; Grace Lin; Christy Brookes; Stephen Fung; Peter J Valk; Ruud Delwel; Bob Löwenberg; Gerald Krystal; R Keith Humphries
Journal:  Blood       Date:  2009-08-10       Impact factor: 22.113

4.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

Review 5.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

6.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

7.  STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output.

Authors:  Geqiang Li; Zhengqi Wang; Yi Zhang; Zizhen Kang; Eleonora Haviernikova; Yongzhi Cui; Lothar Hennighausen; Richard Moriggl; Demin Wang; William Tse; Kevin D Bunting
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

8.  Stat5 is essential for early B cell development but not for B cell maturation and function.

Authors:  Xuezhi Dai; Yuhong Chen; Lie Di; Andrew Podd; Geqiang Li; Kevin D Bunting; Lothar Hennighausen; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

9.  A critical role for Lyn in acute myeloid leukemia.

Authors:  Cédric Dos Santos; Cécile Demur; Valérie Bardet; Nais Prade-Houdellier; Bernard Payrastre; Christian Récher
Journal:  Blood       Date:  2007-12-03       Impact factor: 22.113

10.  Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Authors:  Virginia M Zaleskas; Daniela S Krause; Katherine Lazarides; Nihal Patel; Yiguo Hu; Shaoguang Li; Richard A Van Etten
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

View more
  7 in total

1.  Functions of the Lyn tyrosine kinase in health and disease.

Authors:  Evan Ingley
Journal:  Cell Commun Signal       Date:  2012-07-17       Impact factor: 5.712

2.  Expression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in mice.

Authors:  Michelle T Graham; Clare L Abram; Yongmei Hu; Clifford A Lowell
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

3.  Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.

Authors:  Toshikage Nagao; Tetsuya Kurosu; Yoshihiro Umezawa; Ayako Nogami; Gaku Oshikawa; Shuji Tohda; Masahide Yamamoto; Osamu Miura
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

4.  Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.

Authors:  N Telford; S Alexander; O J McGinn; M Williams; K M Wood; A Bloor; V Saha
Journal:  Blood Cancer J       Date:  2016-04-08       Impact factor: 11.037

5.  Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing.

Authors:  Wibowo Arindrarto; Daniel M Borràs; Ruben A L de Groen; Redmar R van den Berg; Irene J Locher; Saskia A M E van Diessen; Rosalie van der Holst; Edith D van der Meijden; M Willy Honders; Rick H de Leeuw; Wina Verlaat; Inge Jedema; Wilma G M Kroes; Jeroen Knijnenburg; Tom van Wezel; Joost S P Vermaat; Peter J M Valk; Bart Janssen; Peter de Knijff; Cornelis A M van Bergen; Erik B van den Akker; Peter A C 't Hoen; Szymon M Kiełbasa; Jeroen F J Laros; Marieke Griffioen; Hendrik Veelken
Journal:  Leukemia       Date:  2020-03-03       Impact factor: 11.528

Review 6.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors:  Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal:  Front Cell Dev Biol       Date:  2022-07-12

7.  Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.

Authors:  Bin Li; Guangsen Zhang; Cui Li; Ruijuan Li; Jingchen Lu; Zhengxi He; Quan Wang; Zhenzi Peng; Jun Wang; Yeping Dong; Chunfang Zhang; Jie Qiong Tan; Nacef Bahri; Yuexiang Wang; Chaojun Duan
Journal:  Oncotarget       Date:  2016-08-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.